EFFECT OF AGE, AND SPLEEN AND TREATMENT STATUS ON MALE REPRODUCTIVE HORMONES AND SOME PHYSIOLOGICAL PARAMETER LEVELS IN PATIENTS WITH BETA-THALASSEMIA MAJOR

Jamela Jouda Jamela Jouda,Wafaa F Al-Mosawy Wafaa F Al-Mosawy,Rajwan Abduljabbar Ghazzay Rajwan Abduljabbar Ghazzay

doi:10.22159/ajpcr.2019.v12i5.30728

Jamela Jouda Jamela Jouda, Wafaa F Al-Mosawy Wafaa F Al-Mosawy + Show 1 more

Open Access

https://doi.org/10.22159/ajpcr.2019.v12i5.30728

Copy DOI

Abstract

Objective: This research was conducted to study the relationship between spleen status and chelation treatment status with the male reproductive hormones and some physiological parameter levels. Methods: A total of 35 males with thalassemia major (TM) patients are recruited. Patients are grouped according to (1) their age into two groups; ˂18 years and ≥18 years, (2) their spleen status into two groups; splenectomize and non-splenectomize, and (3) their chelation treatment status into two groups; regulation and irregulation. Body mass index (BMI) was calculated and blood was collected from all patients just before blood transfusion session. Hb, ABO blood groups, ferritin, and hormone (luteinizing hormone [LH], follicle-stimulating hormone [FSH], testosterone, prolactin, and cortisone) levels were determined. Results: The highest frequency of thalassemia was in Group O and the lowest was in AB. BMI was higher in TM patients aged ≥18 years, TM patients with splenectomize, and TM patient who take the treatment irregularly. TM patients aged ≥18 years have high level of LH, FSH, and testosterone. TM patients without splenectomize have higher FSH, prolactin, and testosterone. TM patients take the treatment regularly have significantly higher testosterone levels and non-significantly lower FSH level. Conclusion: The levels of cortisol and prolactin hormones are not disturbed in TM patients and not associated with the rate of transfusion, but the level of Hb and ferritin leads to underweight in BMI and may lead to endocrine dysfunction, especially sexual hormones (FSH, LH, and testosterone). These BMI and sex hormones are related to age, spleen, and treatment status.

Highlights

The result of estimated parameters in all groups is showed in Table 2; it showed that thalassemia major (TM) patients aged18 years have significant higher Hb value than those who aged ≥18 years while TM patients aged ≥18 years have significant higher Body mass index (BMI) value
According to chelation treatment status, TM patients who take the treatment irregularly have significant higher BMI and ferritin values compared to who take the treatment regularly
BMI was higher in TM patients aged ≥18 years, in TM patient who takes the chelation treatment irregularly, and TM patients with splenectomize compared to TM patients aged18 years, TM patients who take the chelation treatment regularly, and TM patients with non-splenectomize, respectively

Summary

Methods

A total of 35 males with thalassemia major (TM) patients are recruited. Patients are grouped according to (1) their age into two groups; ˂18 years and ≥18 years, (2) their spleen status into two groups; splenectomize and non-splenectomize, and (3) their chelation treatment status into two groups; regulation and irregulation. A total of 35 Iraqi male with beta-thalassemia major (TM) patients are recruited from thalassemia center/Children’s Teaching Hospital, Kerbala/Iraq, at the age of 14–29 years. The age, blood groups, spleen status, and treatment status are recorded from the profile of all patients. Their age into two groups; ˂18 years and ≥18 years 2 Their spleen status into two groups; splenectomize and nonsplenectomize 3. Their chelation treatment status into two groups; regulation and irregulation

Results

Discussion

Conclusion